Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.56 |
| ▸ | RARG | P13631 | 13/20 | 0.56 |
| ▸ | RARA | P10276 | 12/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.52 |
| ▸ | RXRA | P19793 | 8/20 | 0.50 |
| ▸ | RXRB | P28702 | 5/20 | 0.50 |
| ▸ | RXRG | P48443 | 3/20 | 0.50 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19697333 | 0.91 | CYP26A1 (0.49) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4427154 | 0.89 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL13950477 | 0.89 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4431065 | 0.89 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4431067 | 0.89 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL7759648 | 0.83 | CYP26A1 (0.62) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL7759651 | 0.83 | CYP26A1 (0.62) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL13950505 | 0.81 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4427135 | 0.81 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4421842 | 0.81 | RARB (0.57) | RARBRARGRARACYP26A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793835-B2 | Methods of using RARγ agonists for cancer treatment | Io Therapeutics, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023097259-A1 | METHODS OF USING RARγ AGONISTS FOR CANCER TREATMENT | Io Therapeutics, Inc. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220184012-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2022-06-16 | — | — | US | disclosed |
| US-20210275478-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2021-09-09 | — | — | US | disclosed |
| US-20210113506-A1 | IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210113507-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-10881628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10004708-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004709-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180133182-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180133179-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180133183-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180133181-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180133180-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9907768-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214575-A1 | RECEPTOR SELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275478-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20180133183-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20210113507-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRG, RXRA, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20220184012-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-10004709-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20180133179-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-10881628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20210113506-A1 | IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-11793835-B2 | Methods of using RARγ agonists for cancer treatment | RARG, RARB, RXRG | RARB 2/4885RARG 1/4885RARA 4/4885 |
| US-20180133180-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20180133181-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-20180133182-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
| US-10004708-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARG 4/4885RARA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.